Saluda Medical, Inc. (ASX:SLD)
Australia · Delayed Price · Currency is AUD | Market Cap | 104.59M |
| Revenue (ttm) | 130.35M +28.2% |
| Net Income | -346.36M |
| EPS | -2.14 |
| Shares Out | 252.02M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 88,460 |
| Open | 0.4200 |
| Previous Close | 0.4050 |
| Day's Range | 0.4100 - 0.4250 |
| 52-Week Range | 0.3600 - 2.6500 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 2.00 (+381.93%) |
| Est. Earnings | Nov 25, 2026 |
About Saluda Medical
Saluda Medical, Inc., a medical device company, develops treatments for chronic neurological conditions in the United States, Australia, Europe, and internationally. The company offers a closed-loop, dose-control platform which senses and measures neural responses to stimulation and automatically adjusts therapy based on real-time neurophysiological feedback. It provides Evoke, an aid in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with failed back surgery syndrome, intr... [Read more]
Financial Performance
In fiscal year 2026, Saluda Medical's revenue was $90.18 million, an increase of 28.17% compared to the previous year's $70.36 million. Losses were -$239.61 million, 60.5% more than in 2025.
Financial numbers in USD Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for SLD stock is "Strong Buy." The 12-month stock price target is $2.00, which is an increase of 381.93% from the latest price.
News
Saluda Medical Earnings Call Transcript: H2 2026
Revenue grew 28% year-over-year to $90.2M in FY 2026, with accelerating momentum and strong U.S. performance. FY 2027 guidance targets 25%–35% revenue growth and further gross margin expansion, driven by new product launches and sales force maturation.
Saluda Medical Annual report: H2 2026
Saluda Medical has published its H2 2026 annual report on August 27, 2026.
Saluda Medical Earnings release: H2 2026
Saluda Medical released its H2 2026 earnings on August 27, 2026, summarizing the period's financial results.
Saluda Medical Slides: H2 2026
Saluda Medical has posted slides in relation to its H2 2026 quarterly earnings report, which was published on August 27, 2026.
Saluda Medical Earnings Call Transcript: Q4 2026
Revenue grew 28% year-over-year to $90.2 million, exceeding guidance, with Q4 up 43%. FDA approval of the CAP24 paddle lead expands the addressable market by 30%. Cash position and operational efficiency improved, supporting continued growth into FY 2027.
Saluda Medical Earnings release: Q4 2026
Saluda Medical released its Q4 2026 earnings on July 29, 2026, summarizing the period's financial results.
Saluda Medical Slides: Q4 2026
Saluda Medical has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on July 29, 2026.
Saluda Medical Earnings Call Transcript: Q3 2026
Q3 saw 34% year-over-year revenue growth, driven by a 55% increase in U.S. patient implants and strong international performance. FY 2026 revenue guidance was raised to $87 million, with gross margin improvements expected from new product launches and operational efficiencies.
Saluda Medical Earnings release: Q3 2026
Saluda Medical released its Q3 2026 earnings on April 30, 2026, summarizing the period's financial results.
Saluda Medical Transcript: NWR Virtual Healthcare Conference
Saluda presented its closed-loop spinal cord stimulation technology, highlighting strong clinical outcomes, reduced therapy burden, and significant U.S. market expansion. Financial results show accelerating revenue, improved gross margins, and increased guidance for fiscal 2026.
Saluda Medical Earnings Call Transcript: H1 2026
Revenue grew 17% year-over-year to $39.4M in H1 FY26, with gross margin up to 49.4% and strong U.S. and international growth. FY26 revenue guidance reaffirmed at $85M, with improved cash burn and adjusted EBITDA expected.
Saluda Medical Quarterly report: H1 2026
Saluda Medical has published its H1 2026 quarterly earnings report on February 25, 2026.
Saluda Medical Earnings release: H1 2026
Saluda Medical released its H1 2026 earnings on February 25, 2026, summarizing the period's financial results.
Saluda Medical Earnings release: Q2 2026
Saluda Medical released its Q2 2026 earnings on January 27, 2026, summarizing the period's financial results.
Saluda Medical Slides: Q2 2026
Saluda Medical has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on January 27, 2026.
Saluda Medical Transcript: Investor update
Raised AUD 231 million and began ASX trading to fund U.S. commercial expansion. Closed-loop spinal cord stimulation technology offers strong clinical outcomes, low therapy burden, and significant market opportunity, with a focus on rapid sales force growth and new reimbursement models.
Saluda Medical Slides: Investor update
Saluda Medical has posted slides in relation to its latest quarterly earnings report, which was published on December 3, 2025.